Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase 3 study of baricitinib in children and adolescents with juvenile idiopathic arthritis
CTR20191227Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in juvenile idiopathic arthritis (JIA), sponsored by Eli Lilly and Company. Started Mar 2020; status: active.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on CTR20191227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191227.